Arena Pharmaceuticals Stock News

Following the market opening Monday, the Dow traded down 0.65% to 35,736.04 while the NASDAQ fell 0.26% to 15,590.13. The SP also fell, dropping 0.46% to 4,690.48. The U.S. has the highest number of

Equity index futures are pointing slightly higher on Monday morning as investors appear to be a little tentative ahead of the Fed meeting later this week. Friday’s Consumer Price Index (CPI) shouldn

Pfizer has agreed to acquire Arena Pharmaceuticals in a $6.7 billion all-cash deal to expand its cancer and inflammatory disease treatment pipeline.

Pfizer is spending $6.7 billion to buy a drugmaker with no products on the market and a focus on developing treatments for inflammatory conditions like Chrohns disease

US drugmaker Pfizer today announced it has reached a $6.7bn deal to acquire Arena Pharmaceuticals, a company developing treatments for several US drugmaker Pfizer today announced it has reached a $6.7bn deal to acquire Arena Pharmaceuticals, a company developing treatments for several immuno-inflammatory diseases.

Stocks looked poised to rise again Monday morning.

Pfizer Inc will buy drug developer Arena Pharmaceuticals for $6.7 billion in cash, to add a promising treatment candidate that targets diseases affecting the stomach and intestine

Pfizer Inc. said Monday it has agreed to acquire Arena Pharmaceuticals Inc. in a deal with a value of about $6.7 billion, sending both stocks sharply higher.

With billions in war chest from sales of covid vaccines, pharma giant Pfizer announced on Monday it has agreed to rival drugmaker Arena Pharmaceuticals Pfizer for $6.7 billion cash or $100 per share. Pfizer said it expects to finance the transaction with existing cash [] The post Pfizer buys rival drugmaker Arena Pharmaceuticals for $6.7 billion cash appeared first on Tech News | Startups News .

BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Monday''s pre-market trading (as of 07.10 A.M. ET).In the Green Arena Pharmaceuticals, Inc. (ARNA) is up over 97% at $9

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and Arena Pharmaceuticals, Inc. (ARNA) have entered into a definitive agreement under which Pfizer will acquire Arena. Pfizer will acquire all the outst…

Our call of the day from Stifel sees the Fed working toward a bubble of the century. Here's what happened before.

Pfizer Buys Pharma Rival Arena In All-Cash Deal Worth $6.7 Billion Shares of Arena Pharmaceuticals have doubled in price in premarket trading after Pfizer announced that it had struck a deal to acquire its smaller rival for $100/share in a deal that values the San Deigo-based Arena at $6.7 billion. Pfizer believes it can finance the deal with cash on hand, and thanks to covid, it sure can. Fattened up with its vaccine profits, Pfizer is clearly seizing the opportunity to put some of that money to work by diversifying and paying growth. Investors in both companies should keep in mind that, as part of the deal, warrants will immediately cease to be outstanding and instead will be converted into the right to receive an amount in cash equal to the product of the excess, if any, of the Merger Consideration over the per-share exercise price of such of the options, multiplied by the number of shares then subject to such Company Option. In the press release, Pfizer''s Mike Gladstone said buying Arena would complement Pfizer''s expertise in immunology, specifically allowing it to better serve patients with immuno-inflammatory diseases. "The proposed acquisition of Arena complements our capabilities and expertise in Inflammation and Immunology, a Pfizer innovation engine developing potential therapies for patients with debilitating immuno-inflammatory diseases with a need for more effective treatment options," said Pfizer''s Mike Gladstone. "Utilizing Pfizer''s leading research and global development capabilities, we plan to accelerate the clinical development of etrasimod for patients with immuno-inflammatory diseases." Read the press release below: Pfizer and Arena Pharmaceuticals, Inc.(Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.

Arena Pharmaceuticals (ARNA) stock is flying higher on Monday thanks to a huge $6.7 billion acquisition deal with Pfizer (PFE). The post ARNA Stock Alert: The Pfizer Deal That Has Arena Pharmaceutical